10/24/2019
Cour Pharmaceuticals Announces Deal with Takeda for Celiac Treatment
Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a small phase 2a study at the annual United European Gastroenterology organization meeting showing that its treatment, CNP-101, cut levels of inflammation-promoting cytokines. The technology was…
Continue Reading
